Literature DB >> 25084610

Predictors of individual tumor local control after stereotactic radiosurgery for non-small cell lung cancer brain metastases.

Adam A Garsa1, Shahed N Badiyan2, Todd DeWees2, Joseph R Simpson2, Jiayi Huang2, Robert E Drzymala2, Igor J Barani1, Joshua L Dowling3, Keith M Rich3, Michael R Chicoine3, Albert H Kim3, Eric C Leuthardt3, Clifford G Robinson4.   

Abstract

PURPOSE: To evaluate local control rates and predictors of individual tumor local control for brain metastases from non-small cell lung cancer (NSCLC) treated with stereotactic radiosurgery (SRS). METHODS AND MATERIALS: Between June 1998 and May 2011, 401 brain metastases in 228 patients were treated with Gamma Knife single-fraction SRS. Local failure was defined as an increase in lesion size after SRS. Local control was estimated using the Kaplan-Meier method. The Cox proportional hazards model was used for univariate and multivariate analysis. Receiver operating characteristic analysis was used to identify an optimal cutpoint for conformality index relative to local control. A P value <.05 was considered statistically significant.
RESULTS: Median age was 60 years (range, 27-84 years). There were 66 cerebellar metastases (16%) and 335 supratentorial metastases (84%). The median prescription dose was 20 Gy (range, 14-24 Gy). Median overall survival from time of SRS was 12.1 months. The estimated local control at 12 months was 74%. On multivariate analysis, cerebellar location (hazard ratio [HR] 1.94, P=.009), larger tumor volume (HR 1.09, P<.001), and lower conformality (HR 0.700, P=.044) were significant independent predictors of local failure. Conformality index cutpoints of 1.4-1.9 were predictive of local control, whereas a cutpoint of 1.75 was the most predictive (P=.001). The adjusted Kaplan-Meier 1-year local control for conformality index ≥ 1.75 was 84% versus 69% for conformality index <1.75, controlling for tumor volume and location. The 1-year adjusted local control for cerebellar lesions was 60%, compared with 77% for supratentorial lesions, controlling for tumor volume and conformality index.
CONCLUSIONS: Cerebellar tumor location, lower conformality index, and larger tumor volume were significant independent predictors of local failure after SRS for brain metastases from NSCLC. These results warrant further investigation in a prospective setting.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25084610     DOI: 10.1016/j.ijrobp.2014.05.047

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  11 in total

1.  Hypofractionated stereotactic radiotherapy for brain metastases from lung cancer : Evaluation of indications and predictors of local control.

Authors:  Takeaki Ishihara; Kazunari Yamada; Aya Harada; Kenta Isogai; Yoshihiro Tonosaki; Yusuke Demizu; Daisuke Miyawaki; Kenji Yoshida; Yasuo Ejima; Ryohei Sasaki
Journal:  Strahlenther Onkol       Date:  2016-05-11       Impact factor: 3.621

2.  Single fraction volumetric modulated arc radiosurgery of brain metastases.

Authors:  A Serna; P P Escolar; V Puchades; F Mata; D Ramos; M A Gómez; A Iglesias; J Salinas; M Alcaraz
Journal:  Clin Transl Oncol       Date:  2015-03-17       Impact factor: 3.405

3.  Local control and radionecrosis of brain metastases from non-small-cell lung cancer treated by hypofractionated stereotactic radiotherapy: Evaluation of predictive factors.

Authors:  Brice Leyrat; Toufic Khalill; Jean-Jacques Lemaire; Melanie Casile; Ioana Molnar; Véronique Dedieu; Vincent Chassin; Guillaume Dupic; Aurélie Bellière; Xavier Durando; Michel Lapeyre; Pierre Verrelle; Julian Biau
Journal:  Clin Transl Radiat Oncol       Date:  2022-06-01

Review 4.  Hair Dye Ingredients and Potential Health Risks from Exposure to Hair Dyeing.

Authors:  Lin He; Freideriki Michailidou; Hailey L Gahlon; Weibin Zeng
Journal:  Chem Res Toxicol       Date:  2022-06-06       Impact factor: 3.973

5.  Local control of brain metastases after stereotactic radiosurgery: the impact of whole brain radiotherapy and treatment paradigm.

Authors:  Ryan T Hughes; Paul J Black; Brandi R Page; John T Lucas; Shadi A Qasem; Kounosuke Watabe; Jimmy Ruiz; Adrian W Laxton; Stephen B Tatter; Waldemar Debinski; Michael D Chan
Journal:  J Radiosurg SBRT       Date:  2016

6.  Role of Gamma Knife® Radiosurgery for the Treatment of Brain Metastases from Gynecological Cancers.

Authors:  Andrew Keller; Rahim Ismail; Peter S Potrebko; Julie Pepe; Meiling Wu; Kunal Saigal; Matthew Biagioli; Ravi Shridhar; Robert Holloway; Melvin Field; Nikhil G Rao
Journal:  Cureus       Date:  2016-12-31

7.  Distant intracranial failure in melanoma brain metastases treated with stereotactic radiosurgery in the era of immunotherapy and targeted agents.

Authors:  Sahaja Acharya; Mustafaa Mahmood; Daniel Mullen; Deshan Yang; Christina I Tsien; Jiayi Huang; Stephanie M Perkins; Keith Rich; Michael Chicoine; Eric Leuthardt; Joshua Dowling; Gavin Dunn; Jesse Keller; Clifford G Robinson; Christopher Abraham
Journal:  Adv Radiat Oncol       Date:  2017-08-12

8.  HyperArc VMAT planning for single and multiple brain metastases stereotactic radiosurgery: a new treatment planning approach.

Authors:  Shingo Ohira; Yoshihiro Ueda; Yuichi Akino; Misaki Hashimoto; Akira Masaoka; Takero Hirata; Masayoshi Miyazaki; Masahiko Koizumi; Teruki Teshima
Journal:  Radiat Oncol       Date:  2018-01-29       Impact factor: 3.481

9.  Dosimetric effect of rotational setup errors in stereotactic radiosurgery with HyperArc for single and multiple brain metastases.

Authors:  Tomohiro Sagawa; Shingo Ohira; Yoshihiro Ueda; Yuichi Akino; Hirokazu Mizuno; Masao Matsumoto; Masayoshi Miyazaki; Masahiko Koizumi; Teruki Teshima
Journal:  J Appl Clin Med Phys       Date:  2019-09-11       Impact factor: 2.102

10.  Performance assessment of two motion management systems for frameless stereotactic radiosurgery.

Authors:  Hao Wang; Zhiyong Xu; Kevin Grantham; Yongkang Zhou; Taoran Cui; Yin Zhang; Bo Liu; Xiao Wang; Irina Vergalasova; Meral Reyhan; Joseph Weiner; Shabbar F Danish; Ning Yue; Ke Nie
Journal:  Strahlenther Onkol       Date:  2020-10-12       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.